pharmacologic response
Recently Published Documents


TOTAL DOCUMENTS

48
(FIVE YEARS 2)

H-INDEX

10
(FIVE YEARS 0)

2021 ◽  
Vol 20 ◽  
pp. S308
Author(s):  
G. Bampi ◽  
R. Rauscher ◽  
M. Ferrer ◽  
D. Joshi ◽  
D. Mark ◽  
...  

Pain ◽  
2020 ◽  
Vol 161 (3) ◽  
pp. 619-629 ◽  
Author(s):  
Rodrigo Benavides ◽  
Olga Vsevolozhskaya ◽  
Stefano Cattaneo ◽  
Dmitri Zaykin ◽  
Ashley Brenton ◽  
...  

2019 ◽  
Author(s):  
Song Yi Bae ◽  
Ning Guan ◽  
Rui Yan ◽  
Katrina Warner ◽  
Aaron S Meyer

AbstractCancer cell sensitivity or resistance is almost universally quantified through a direct or surrogate measure of cell number. However, compound responses can occur through many distinct phenotypic outcomes including changes in cell growth, apoptosis, and non-apoptotic cell death. These outcomes have distinct effects on the tumor microenvironment, immune responses, and resistance mechanisms. Here, we show that quantifying cell viability alone is insufficient to distinguish between these compound responses. Using an alternative assay and drug response analysis amenable to high-throughput measurement, we find that compounds with identical viability outcomes can have very different effects on cell growth and death. Moreover, compound pairs with additive cell growth and death effects can appear synergistic when only assessed by viability. Overall, these results demonstrate an approach to incorporating measurements of cell death when characterizing a pharmacologic response.Summary PointsMeasurements of solely live cell numbers mask important differences in compound effects.Additive effects on growth and death rates can appear synergistic when analyzed solely via live cell number.Automated imaging can provide reasonable throughput to analyze cell response in terms of cell growth and death, and endpoint analysis is similarly informative.


2018 ◽  
Vol 46 (8) ◽  
pp. 956-969 ◽  
Author(s):  
Gordon C. Hard

The important renal tumors that can be induced by exposure of rats to chemical carcinogens are renal tubule tumors (RTTs) derived from tubule epithelium; renal pelvic carcinoma derived from the urothelial lining of the pelvis; renal mesenchymal tumors (RMTs) derived from the interstitial connective tissue; and nephroblastoma derived from the metanephric primordia. However, almost all of our knowledge concerning mechanisms of renal carcinogenesis in the rodent pertains to the adenomas and carcinomas originating from renal tubule epithelium. Currently, nine mechanistic pathways can be identified in either the rat or mouse following chemical exposure. These include direct DNA reactivity, indirect DNA reactivity through free radical formation, multiphase bioactivation involving glutathione conjugation, mitotic disruption, sustained cell proliferation from direct cytotoxicity, sustained cell proliferation by disruption of a physiologic process (alpha 2u-globulin nephropathy), exaggerated pharmacologic response, species-dominant metabolic pathway, and chemical exacerbation of chronic progressive nephropathy. Spontaneous occurrence of RTTs in the rat will be included since one example is a confounder for interpreting kidney tumor results in chemical carcinogenicity studies in rats.


Sign in / Sign up

Export Citation Format

Share Document